KCKun Cheng

Kun Cheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kun Cheng has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Huifang Liang

    Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    3 shared publications
  • Wanguang Zhang

    Tongji Hospital

    3 shared publications
  • Xing Yang

    Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430030, China

    3 shared publications
  • Dao Wen Wang

    Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    2 shared publications
  • Yuxin Zhang

    Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    2 shared publications
  • Bin Guo

    Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China

    1 shared publication

Latest Publications

  • Open Access

    Mitochondrial Distress Signals at the Heart–Liver Interface: Molecular Links Between MASLD and Heart Failure

    by Xing Yang, Kun Cheng, Chen Chen, Yuxin Zhang, Dao Wen Wang

    Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure (HF) frequently coexist within a shared cardiometabolic environment, yet their mitochondrial abnormalities are stage- and phenotype-dependent rather than uniform. In MASLD, mitochondrial adaptation evolves from increased oxidative metabolism in early steatosis toward impaired respiratory flexibility, oxidative stress, and defective quality control with disease progression, whereas the failing myocardium develops reduced energetic reserve and altered substrate utilization. These organ-specific disturbances can modify mitochondria-linked metabolites, mitochondrial damage-associated molecular patterns, stress-responsive endocrine mediators, and extracellular vesicle-associated mitochondrial cargo. However, similar mitochondrial abnormalities or circulating signals in the liver and heart do not by themselves establish direct inter-organ communication. This review distinguishes shared systemic drivers and organ-intrinsic mitochondrial stress from source-resolved cardio-hepatic signaling, highlighting hepatic ketogenesis, fibroblast growth factor 21 (FGF21), mitochondrial DNA (mtDNA)-dependent inflammatory pathways, and extracellular vesicle-mediated cargo transfer as mechanistically distinct examples with different levels of evidence. We further discuss biomarker limitations, HF-related hemodynamic liver injury, and therapeutic strategies ranging from established cardiometabolic unloading to emerging mitochondria-centered interventions. A stage-, phenotype-, and source-resolved framework may improve interpretation of mitochondrial signals and guide future mechanistic and translational studies in the MASLD–HF overlap.


  • Open Access

    The circadian architecture of tumor immunity: mechanistic insights and treatment strategies

    by Hao Wang, Bin Guo, Danfeng Li, Yuxi Liu, Kun Cheng, Wanguang Zhang, Huifang Liang

  • Open Access

    Mitochondrial Distress Signals at the Heart-Liver Interface: Molecular Links Between MASLD and Heart Failure

    by Xing Yang, Kun Cheng, Yuxin Zhang, Daowen Wang

    Mitochondrial distress signaling provides a mechanistic link between local organelle dysfunction and systemic cardio-hepatic remodeling. In metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure (HF), hepatic nutrient overload and cardiac energy-demand mismatch generate distinct but convergent disturbances in oxidative metabolism, mitochondrial dynamics, mitophagy, and redox control. These changes alter the production, localization, and release of mitochondria-linked metabolites, mitochondrial damage-associated molecular patterns, and extracellular vesicle-associated mitochondrial cargo, enabling stressed tissues to influence distant organs. This review examines how stage-dependent bioenergetic remodeling and defective mitochondrial quality control shape distress-signal generation in MASLD and HF. We further discuss the context-dependent roles of succinate, β-hydroxybutyrate, mitochondrial DNA-dependent innate immune signaling, and extracellular vesicle-mediated cargo transport in heart–liver communication. Finally, we summarize established cardiometabolic therapies and emerging mitochondria-centered strategies that reduce substrate overload, restore organelle resilience, or limit inflammatory signal propagation. Integrating these mechanisms positions mitochondrial distress signaling as a unifying framework for understanding the bidirectional relationship between MASLD and HF and for identifying biomarkers and therapeutic targets at the heart-liver interface.

  • Open Access

    Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma

    by Kun Cheng, Ning Cai, Xing Yang, Danfeng Li, Jinghan Zhu, Hui Yuan Yang, Sha Liu, Deng Ning, Huifang Liang, Jianping Zhao, et al.

    Background and Aims: Immune checkpoint inhibitors have revolutionized systemic HCC treatment. Nevertheless, numerous patients are refractory to immune checkpoint inhibitor therapy. It is currently unknown whether diet therapies such as short-term starvation (STS) combined with immune checkpoint inhibitors can be used to treat HCC. This study aimed to investigate whether STS could sensitize HCC tumors to immunotherapy. Approach and Results: STS was found to attenuate tumor progression by inducing tumor-associated macrophages (TAMs) to switch to an antitumoral phenotype, enhancing phagocytosis of tumor cells, and stimulating subsequent antitumor immunity of CD8 + T cells as demonstrated in 3 HCC mouse models, NCG mice, and Rag2-KO mice. Furthermore, STS combined with anti-programmed cell death 1/ligand 1 (anti-PD-1/L1) suppressed tumor progression, while the efficacy of PD-L1 was improved when combined with STS. Mechanistically, TAM-derived exosomal PD-L1 (exoPD-L1) impairs the efficacy of anti-PD-1/L1. STS attenuates exoPD-L1 secretion from TAM by regulating the fructose diphosphatase 1 (FBP1) /Akt/Rab27a axis. Modulating FBP1/Akt/Rab27a axis potentiates the anti-PD-L1 response using 2 liposomal delivery systems and macrophage adoptive transfer. Conclusions: This study describes the immunomodulatory effects of STS and provides a rationale for its application as an adjuvant in HCC immunotherapy.


  • Top Cited Papers
    Open Access

    Tumor‐associated macrophages in liver cancer: From mechanisms to therapy

    by Kun Cheng, Ning Cai, Jinghan Zhu, Xing Yang, Huifang Liang, Wanguang Zhang

    Multidimensional analyses have demonstrated the presence of a unique tumor microenvironment (TME) in liver cancer. Tumor‐associated macrophages (TAMs) are among the most abundant immune cells infiltrating the TME and are present at all stages of liver cancer progression, and targeting TAMs has become one of the most favored immunotherapy strategies. In addition, macrophages and liver cancer cells have distinct origins. At the early stage of liver cancer, macrophages can provide a niche for the maintenance of liver cancer stem cells. In contrast, cancer stem cells (CSCs) or poorly differentiated tumor cells are key factors modulating macrophage activation. In the present review, we first propose the origin connection between precursor macrophages and liver cancer cells. Macrophages undergo dynamic phenotypic transition during carcinogenesis. In this course of such transition, it is critical to determine the appropriate timing for therapy and block specific markers to suppress pro‐tumoral TAMs. The present review provides a more detailed discussion of transition trends of such surface markers than previous reviews. Complex crosstalk occurs between TAMs and liver cancer cells. TAMs play indispensable roles in tumor progression, angiogenesis, and autophagy due to their heterogeneity and robust plasticity. In addition, macrophages in the TME interact with other immune cells by directing cell‐to‐cell contact or secreting various effector molecules. Similarly, tumor cells combined with other immune cells can drive macrophage recruitment and polarization. Despite the latest achievements and the advancements in treatment strategies following TAMs studies, comprehensive discussions on the communication between macrophages and cancer cells or immune cells in liver cancer are currently lacking. In this review, we discussed the interactions between TAMs and liver cancer cells (from cell origin to maturation), the latest therapeutic strategies (including chimeric antigen receptor macrophages), and critical clinical trials for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) to provide a rationale for further clinical investigation of TAMs as a potential target for treating patients with liver cancer.